About Longevitytech.fund
Longevitytech.fund is a venture capital firm founded in 2019. It is primarily based out of Boca Raton, United States. As of Dec 2023, Longevitytech.fund has invested in 33 companies. It primarily invests in Seed round in United States based startups. Its investments are spread across a wide range of sectors from Life Sciences to High Tech and HealthTech. Most recently it participated in the $***** Seed round of MitoRx Therapeutics Overall, Longevitytech.fund portfolio has seen 2 IPOs and 1 acquisition, namely Genflow Biosciences and Nightingale. A lot of funds co-invest with Longevitytech.fund, with names like Khosla Ventures sharing a substantial percentage of its portfolio. Longevitytech.fund has team of 10 people including 5 partners.Key Metrics
Team Members
Portfolio Count
Portfolio Sectors
Portfolio Locations
Rounds of Entry
Seed
Portfolio IPOs
Portfolio Acquisitions
Portfolio Soonicorns
Longevitytech.fund's List of Top Investments
Longevitytech.fund has a portfolio of 33 companies. Their most notable investments are in MitoRx Therapeutics and Vesttoo.Their portfolio spans across United States, United Kingdom, Belgium and 5 more locations. They have invested in Life Sciences, High Tech, HealthTech and 6 other sectors, across stages such as Seed stage. Here is the list of top investments by Longevitytech.fund:Juvena Therapeutics is engaged in the development of protein-based therapeutics that promote tissue generation in the elderly. The company has developed a discovery platform for screening restored muscle function which can be developed to other tissue types. The company has developed a protein cocktail which can improve the ability of aged muscle to heal and regenerate and also to look youthful and active.
Key facts about Juvena Therapeutics
- Founded Year: 2017
- Location: San Mateo (United States)
- Valuation: $*****
- Stage: Series B
- Total Funding till date: $86.3M
- Employee Count: 42 as on Aug 31, 2026
- Investors: Mubadala, Felicis Ventures and 23 Others
- Latest Funding Round: Series B, Jun 27, 2025, $*****
- Highlight: Editors' Pick
Rejuvenation Technologies is developing nucleoside-modified TERT mRNA. The nucleoside-modified TERT mRNA is used to extend the telomeres. It is based on the technology that telomere shortening affects cell function. The company has developed in-vivo based therapeutics (in-vivo testing phase) and cell therapies (out-licensing phase) for aging and treating fatal diseases.
Key facts about Rejuvenation Technologies
- Founded Year: 2012
- Location: Mountain View (United States)
- Valuation: $*****
- Stage: Seed
- Total Funding till date: $15.2M
- Employee Count: 21 as on Sep 30, 2026
- Investors: Khosla Ventures, Shanda and 14 Others
- Latest Funding Round: Seed, Sep 24, 2026, $*****
- Highlight: Editors' Pick
3. Remedium Bio
Developer of gene therapies for a broad range of diseases. The company is developing a pipeline of a broad range of therapies for immune and age-related conditions which includes RMD 1101 for rheumatology, RMD 1202 for endocrinology, RMD 1501 for neurology, and RMD 1201 for Type-1 diabetes.
Key facts about Remedium Bio
- Founded Year: 2020
- Location: Needham (United States)
- Stage: Series A
- Total Funding till date: $15M
- Employee Count: 19 as on Aug 31, 2026
- Investors: Lilly, Longevitytech.fund and 10 Others
- Latest Funding Round: Series A, Aug 10, 2026, $*****
Key facts about Repair Biotechnologies
- Founded Year: 2018
- Location: Syracuse (United States)
- Stage: Series A
- Total Funding till date: $25.8M
- Employee Count: 10 as on Aug 31, 2026
- Investors: Longevitytech.fund, Thynk Capital and 5 Others
- Latest Funding Round: Series A, Nov 14, 2025, $*****
- Highlight: Editors' Pick
Developer of new treatments to restore healthy mitochondrial metabolism in patients. The company's small molecule asset, MTRX31, targets the elimination of ectopic fat from affected organs, in people with metabolically unhealthy obesity, by resetting mitochondrial function rather than suppressing appetite.
Key facts about MitoRx Therapeutics
- Founded Year: 2021
- Location: Harwell (United Kingdom)
- Stage: Seed
- Total Funding till date: $12.2M
- Employee Count: 19 as on Sep 30, 2026
- Investors: Wren Capital, Longevitytech.fund and 21 Others
- Latest Funding Round: Seed, Nov 17, 2025, $*****
- Highlight: Editors' Pick
Longevitytech.fund's Year-on-Year Investment Trends
Longevitytech.fund has invested in 33 companies over the last 7 years, with an average of 2 new investments annually in the last 5 years. Its most recent first time investment was in Rejuvenation Technologies and most recent follow-on round was in MitoRx Therapeutics.Year | No. of Investments | ||
|---|---|---|---|
1st Round | Follow-on | Total | |
2026 (YTD) | 0 | 0 | 0 |
2025 | 0 | 0 | 0 |
2024 | 0 | 0 | 0 |
2023 | 2 | 1 | 3 |
2022 | 4 | 1 | 5 |
2021 | 5 | 0 | 5 |
2020 | 1 | 0 | 1 |
2019 | 1 | 0 | 1 |
Longevitytech.fund's Investments by Stage
Longevitytech.fund has made 13 investments in Seed stage with an average round size of $4.55M.Longevitytech.fund's Investments by Sector
Longevitytech.fund has a diverse portfolio, with companies operating in the Life Sciences, High Tech, HealthTech, Consumer and FinTech. Notably, it has invested in 24 Tech companies, 19 Enterprise (B2B) companies, 8 Consumer (B2C) companies and at least 6 companies focusing on Software.Sector | No. of Investments |
|---|---|
Life Sciences | 9 |
High Tech | 4 |
HealthTech | 3 |
Consumer | 1 |
FinTech | 1 |
Others | 1 |
Note: We have considered here, only first round of investments
Longevitytech.fund's Investments by Geography
Longevitytech.fund has made most investments in United States (6), followed by United Kingdom where it has made 3 investments.Country | No. of Investments |
|---|---|
United States | 6 |
United Kingdom | 3 |
Austria | 1 |
Germany | 1 |
Israel | 1 |
Others | 1 |
Note: We have considered here, only first round of investments
Longevitytech.fund's recent investments
Longevitytech.fund has not made any investment in 2026 so far.Here are the most recent investments by Longevitytech.fund:
Filter this listDate | Company | Location | Round Details | Round Amount | Co-Investors |
|---|---|---|---|---|---|
Dec 13, 2023 | United Kingdom | Seed | 1816 | ||
Sep 06, 2023 | United States | Seed | 1450 | [+4] | |
Jan 18, 2023 | United States | Seed | 6005 | [+7] | |
Sep 28, 2022 | Netherlands | Seed | 5712 | ||
Aug 16, 2022 | United States | Seed | 5960 | [+5] |
IPOs and Publicly Listed companies in Longevitytech.fund's Portfolio
2 of Longevitytech.fund's portfolio companies have become public. Nightingale got listed on the Athens Exchange (ATHEX), in Mar 2025 and Genflow Biosciences got listed on the London Stock Exchange (LSE) at marketcap of $36.9M.Here are Longevitytech.fund's portfolio companies that went public:
Company | IPO Date | First Invested on | First Round of Investment | Round Size |
|---|---|---|---|---|
Mar 19, 2025 | - | - | 3872 | |
Jan 17, 2022 | - | - | 2325 |
Acquired companies in Longevitytech.fund's Portfolio
1 company from Longevitytech.fund's portfolio has been acquired. The most recent acquisition was Yolife in Jul 2021 by Nightingale for $*****.Here are Longevitytech.fund's portfolio companies that got acquired most recently:
Company | Acquisition Date | First Invested on | First Round of Investment | Round Size |
|---|---|---|---|---|
Jul 21, 2021 | Sep 01, 2020 | Seed | 3875 |
Team profile of Longevitytech.fund
Longevitytech.fund has a team of 10 members including 5 Partners and 2 Principals located in United States and Czech Republic. Longevitytech.fund's team does not sit on the board of any company as of now.Here is a list of all team members in Longevitytech.fund:
Name | Designation | Location | Board Memberships | Contact Details |
|---|---|---|---|---|
Partner | Palo Alto | - | ||
Partner | Prague | - | ||
Partner | Czech Republic | - | ||
Partner | - | - | ||
Partner | United States | - | - | |
Principal | - | - | ||
Principal | United States | - |
Co-investors of Longevitytech.fund
Over the past 7 years, 68 investors have co-invested in Longevitytech.fund's portfolio companies. This includes funds and angels.
- Invested before Longevitytech.fund: Y Combinator, HHS and 4 others have invested in rounds before Longevitytech.fund. There are 2 companies where Y Combinator has invested before Longevitytech.fund and 1 company where HHS has invested before Longevitytech.fund.
- Top Co-investors of Longevitytech.fund: 35 investors entered a company along with Longevitytech.fund. These include investors like Khosla Ventures (2 companies).
- Invested after Longevitytech.fund: A total of 27 investors have invested in Longevitytech.fund's portfolio after their investments. Top Investors include LifeSpan Vision Ventures (3 companies), APEX Ventures (2 companies) and Jetstream Venture Fund (1 company).
Recent News related to Longevitytech.fund
•
MitoRx Therapeutics Closes Seed Extension FinancingFinSMEs•Dec 14, 2023•MitoRx Therapeutics, UK Innovation Science & Seed Fund, Wren Capital, Longevitytech.fund and 2 others
•
Rejuvenation Technologies Raises $10.6M in Seed FinancingFinSMEs•Sep 06, 2023•Rejuvenation Technologies, Khosla Ventures, Shanda, Asymmetry Ventures and 3 others
•
Cleara Biotech Raises $2.5 Million in Seed Financing to Advance FOXO4-Therapeutics Pipeline for Treating Cancer and Chronic DiseasesHerald Chronicle•Sep 28, 2022•Cleara, Apollo Health Ventures, Curie Capital, ROM Utrecht Region and 1 other
•
Remedium Bio Closes $2.3M Expanded Seed FundingFinSMEs•Aug 16, 2022•Remedium Bio, Sherwood Ventures, Longevitytech.fund, Hanicar Security
•
MitoRx Therapeutics Announces Seed Financing to Advance its Mitochondrial-Protective Therapeutics to Treat Degenerative DiseasesPR Newswire•Apr 25, 2022•MitoRx Therapeutics, UK Innovation Science & Seed Fund, Wren Capital, Longevitytech.fund and 3 others
•
Sampling Human Raises $2 Million to Support the Development of Engineered Cells for Single Cell AnalysisBusiness Wire•Apr 13, 2022•Sampling Human, i&i Bio, Formic Ventures, Longevitytech.fund
•
NOVOS Closes $3.15M, Aims to Extend Healthy Human Lifespan With Science-Based SupplementsBusiness Wire•Oct 01, 2021•NOVOS, Resolute Ventures, Arkitekt Ventures, Longevitytech.fund and 1 other
•
•
